-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VHyX7QNzMdT0xpULPO90FvuBWsk6gKdmOi19c2HkE4uynnKRCUPW3p2e7xVyO/f/ aWIpXIe5ZFIIqiGFRiSQzQ== 0000950116-01-501080.txt : 20020410 0000950116-01-501080.hdr.sgml : 20020410 ACCESSION NUMBER: 0000950116-01-501080 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20011107 ITEM INFORMATION: Other events FILED AS OF DATE: 20011108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 1778896 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 8-K 1 eightk.txt EIGHTK.TXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2001 ---------------- Generex Biotechnology Corporation - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-25169 98-0178636 - ---------------------------- --------- ------------------- (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J 2G2 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 416/364-2551 ------------------------- - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events. This is an update to the description of the registrant's pending legal proceeding with Sands Brothers & Co. Ltd. that is set forth in the registrant's Report on Form 10-K for the year ended July 31, 2001. On November 7, 2001, the arbitration panel issued an award again requiring the registrant to issue to Sands a warrant to purchase 1,530,020 shares of the registrant's common stock purportedly pursuant to and in accordance with the terms of the October 1997 letter agreement. The registrant believes that the arbitration panel's award does not accord with the direction of the New York State Appellate Division, First Department, as set forth in its order remanding the proceeding to the arbitration panel for further consideration. The registrant intends to oppose any motion filed in court to confirm the award and to file a motion in court to vacate the award. The registrant is not able to estimate an amount or range of potential loss from this legal proceeding at the present time. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEREX BIOTECHNOLOGY CORPORATION Dated: November 8, 2001 By: /s/ E. Mark Perri ---------------- ------------------------------- E. Mark Perri, Chairman and CFO -----END PRIVACY-ENHANCED MESSAGE-----